#USA #Neuros Medical #Altius System #Arden Hills #Medicare Status

Neuros Medical's Groundbreaking Announcement

Neuros Medical, Inc., a pioneering firm in the medical device sector, has recently revealed a transformative development for patients suffering from chronic pain following limb amputations. The company has secured Transitional Pass-Through (TPT) status for its innovative ALTIUS® System as part of the Centers for Medicare & Medicaid Services (CMS) finalized ruling for the Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC).

Expanding Access for Patients

Effective from January 1, 2027, this crucial approval enables Medicare beneficiaries experiencing chronic post-amputation pain to access the ALTIUS System in both Hospital Outpatient Departments and Ambulatory Surgical Centers. The introduction of a new Category C-code facilitates additional reimbursement specifically for the ALTIUS System, layering above the standard APC procedural payment rates.

The ALTIUS System is recognized as a valuable aid in addressing chronic, intractable phantom and residual pain for adult amputees. Chronic pain after amputation, including phantom limb sensations and residual limb pain, is a significant issue for many in the amputee community. It not only leads to reduced mobility and reliance on opioids but also severely impacts the quality of life of patients.

Transforming Pain Management Approaches

Historically, traditional treatments for post-amputation pain were limited, often resulting in inadequate relief for those affected. With a focus on innovative solutions, the ALTIUS System stands out as a life-changing option. It utilizes direct electrical nerve stimulation to target pain at its source, significantly improving the management of post-amputation pain.

Before this advocacy for TPT status, outpatient facilities faced significant monetary hurdles when it came to the adoption of advanced neurostimulation technologies. These financial disincentives resulted in limited availability of care options, despite the strong patient demand. The approval for transitional pass-through payments addresses these issues head-on, ensuring that healthcare providers can offer vital treatments without the threat of financial loss.

Ensuring Facility Financial Viability

With the newly provided reimbursement structure, facilities can now incorporate the ALTIUS System into their services without struggling with negative operating margins. This adjustment is crucial for hospital administrations and surgical centers, as it provides a more predictable financial landscape. Ambulatory Surgical Centers, in particular, stand to benefit from this ruling, as it alleviates previous fiscal barriers, encouraging them to adopt advanced pain management therapies.

David Veino, President and CEO of Neuros Medical, expressed his enthusiasm about this landmark CMS ruling, noting it affirms the importance of the ALTIUS System in improving the lives of patients dealing with chronic post-amputation pain. He emphasized that the previous financial challenges associated with acquiring such technology have now been resolved, allowing patients to access this revolutionary therapy in settings that best suit their needs.

Support for Clinicians and Facilities

Neuros Medical acknowledges that transitioning into this new reimbursement framework can be complex. Therefore, they have equipped their dedicated Market Access and Reimbursement team to assist healthcare professionals. This support includes coding guidance, billing assistance, and an overview of the health economics surrounding the ALTIUS System, ensuring a smooth integration into clinical practices.

Looking Ahead

The transitional pass-through payment will remain effective for a three-year period commencing January 1, 2027. This significant time frame allows ample opportunity for facilities to adopt the technology while providing necessary services to patients in need.

In conclusion, the ALTIUS Direct Electrical Nerve Stimulation System is not merely an innovative product but a beacon of hope for the amputee community. With this recent advancement, Neuros Medical is poised to alleviate pain and restore life for those affected by chronic post-amputation pain, ensuring that access barriers are dismantled for the betterment of patient care.